Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 1

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 1
---
 of
the earlier effective registration statement for the same offering. ¨

If this Form is a post-effective amendment filed
pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering. ¨

Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.

Emerging growth company ¨

If an emerging growth company that prepares its
financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standard provided pursuant to Section 7(a)(2)(B) of the Securities Act.
¨

The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.

The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and we are not soliciting an offer to buy these securities in any state or jurisdiction where the offer or sale is not permitted.

<div align='center'>PRELIMINARY PROSPECTUS—SUBJECT TO COMPLETION, DATED JANUARY 17, 2025

358,750,000,000 Ordinary Shares Representing 35,875,000 American Depositary Shares

___________________</div>

This prospectus relates to
the potential offer and sale from time to time by C/M Capital Master Fund, LP, or the Selling Shareholder, of up to 358,750,000,000 of
our ordinary shares, nominal value £0.00005 per share, or Ordinary Shares, represented by 35,875,000 American Depositary Shares, or Depositary Shares, that have been or may be issued by us to the Selling Shareholder
pursuant to a Securities Purchase Agreement, dated as of January 17, 2025, by and between us and C/M, or the Purchase Agreement,